Literature DB >> 498424

Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

A Trouet, D Deprez-De Campeneere.   

Abstract

Experimental data on the pharmacokinetic, toxic and therapeutic properties of daunorubicin-DNA and doxorubicin-DNA complexes are reviewed and summarized as well as the available reports on clinical trials performed with these anthracycline-DNA complexes. These results are discussed in view of the further development of the drug-carrier concept of cancer chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 498424     DOI： 10.1007/bf00253110

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  18 in total

1.  Kinetic response of human lymphoid cells to adriamycin-DNA complex in vitro.

Authors:  B Barlogie; B Drewinko; R S Benjamin; E J Freireich
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

Review 2.  Perspectives in cancer research. Increased selectivity of drugs by linking to carriers.

Authors:  A Trouet
Journal:  Eur J Cancer       Date:  1978-02       Impact factor: 9.162

3.  Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA.

Authors:  A Langslet; I Oye; S O Lie
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

4.  Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia.

Authors:  G Cornu; J L Michaux; G Sokal; A Trouet
Journal:  Eur J Cancer       Date:  1974-11       Impact factor: 9.162

5.  Letter: DNA-daunorubicin complex: preliminary trials in human leukaemia.

Authors:  G Sokal; A Trouet; J L Michaux; G Cornu
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

6.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Uptake of the daunorubicin-DNA complex in cultured fibroblasts.

Authors:  C Peterson; G Noël; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors:  D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333
View more
  7 in total

1.  Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

Authors:  R Baurain; D Deprez-De Campeneere; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors:  P Gunvén; N O Theve; C Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

4.  Cryo-shocked cancer cells for targeted drug delivery and vaccination.

Authors:  Tianyuan Ci; Hongjun Li; Guojun Chen; Zejun Wang; Jinqiang Wang; Peter Abdou; Yiming Tu; Gianpietro Dotti; Zhen Gu
Journal:  Sci Adv       Date:  2020-12-09       Impact factor: 14.136

5.  Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway.

Authors:  Pei-Chen Huang; Wei-Wen Kuo; Chia-Yao Shen; Yu-Feng Chen; Yueh-Min Lin; Tsung-Jung Ho; V Vijaya Padma; Jeng-Fan Lo; Chih-Yang Huang; Chih-Yang Huang
Journal:  Int J Mol Sci       Date:  2016-09-21       Impact factor: 5.923

6.  Isolated cell-bound membrane vesicles (CBMVs) as a novel class of drug nanocarriers.

Authors:  Yang Zhang; Yang Liu; Wendiao Zhang; Qisheng Tang; Yun Zhou; Yuanfang Li; Tong Rong; Huaying Wang; Yong Chen
Journal:  J Nanobiotechnology       Date:  2020-05-06       Impact factor: 10.435

Review 7.  Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.

Authors:  Paweł Sobczuk; Magdalena Czerwińska; Marcin Kleibert; Agnieszka Cudnoch-Jędrzejewska
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.